A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the Treatment of Patients With Age-Related Macular Degeneration
Sponsor: PPD Development, LP
Terminated
The study terminated for safety reasons
Other terminated trials from PPD Development, LP
Other Age-related Macular Degeneration trials with similar outcome
Listed as NCT03869684, this PHASE2 trial focuses on Age-related Macular Degeneration and remains terminated or withdrawn. Sponsored by PPD Development, LP, it has been updated 15 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Jun 2025 — Present [monthly]
Terminated PHASE2
-
Oct 2024 — Jun 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
▶ Show 10 earlier versions
-
May 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jan 2021 — May 2021 [monthly]
Terminated PHASE2
-
May 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Dec 2019 — May 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE2
-
Aug 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE2
First recorded
Feb 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PPD Development, LP
- Senju Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .